Association of allelic variants of factor V Leiden, prothrombin and methylenetetrahydrofolate reductase with thrombosis or ocular involvement in Behçet's disease: A systematic review and meta-analysis

Autoimmunity Reviews

Volumn 12, Issue 5, 2013, Pages 607-616

  Chamorro, Antonio Javier ^a,b   Marcos, Miguel ^a,c   Hernández García, Ignacio ^c   Calvo, Antonia ^a   Mejia, Juan Carlos ^a   Cervera, Ricard ^a   Espinosa, Gerard ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b University Hospital of Ourense   (Spain)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Behcet syndrome; Factor V; Genetic; Meta analysis; Methylenetetrahydrofolate reductase; Polymorphism; Prothrombin

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5 LEIDEN; PROTHROMBIN;

BEHCET DISEASE; EMBASE; EYE DISEASE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MEDLINE; META ANALYSIS; REVIEW; SENSITIVITY ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; THROMBOSIS; TURKEY (REPUBLIC);

ALLELES; BEHCET SYNDROME; EYE DISEASES; FACTOR V; FEMALE; GENETIC VARIATION; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); PROTHROMBIN; RANDOM ALLOCATION; THROMBOSIS;

EID: 84875273705     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.11.001     Document Type: Review

References (50)

1. Jennette J., Falk R., Bacon P., Basu N., Cid M., Ferrario F., et al. Revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 2012, [Published Online First: 8 October 2012]. 10.1002/art.37715.
2. Yazici Y., Yurdakul S., Yazici H. Behcet's syndrome. Curr Rheumatol Rep 2010, 12:429-435.
3. Calamia K.T., Schirmer M., Melikoglu M. Major vessel involvement in Behcet's disease: an update. Curr Opin Rheumatol 2011, 23:24-31.
4. Seyahi E., Yurdakul S. Behcet's syndrome and thrombosis. Mediterr J Hematol Infect Dis 2011, 3:e2011026.
5. Mendoza-Pinto C., Garcia-Carrasco M., Jimenez-Hernandez M., Jimenez Hernandez C., Riebeling-Navarro C., Nava Zavala A., et al. Etiopathogenesis of Behcet's disease. Autoimmun Rev 2010, 9:241-245.
6. Duzgun N., Ayaslioglu E., Tutkak H., Sahin M., Aydintug O., Olmez U. Plasma thrombomodulin levels in patients with Behcet's disease. Rheumatol Int 2003, 23:130-133.
7. Navarro S., Ricart J.M., Medina P., Vaya A., Villa P., Todoli J., et al. Activated protein C levels in Behcet's disease and risk of venous thrombosis. Br J Haematol 2004, 126:550-556.
8. Zhou Z.Y., Chen S.L., Shen N., Lu Y. Cytokines and Behcet's disease. Autoimmun Rev 2012, 11:699-704.
9. Ricart J.M., Ramon L.A., Vaya A., Espana F., Santaolaria M.L., Todoli J., et al. Fibrinolytic inhibitor levels and polymorphisms in Behcet disease and their association with thrombosis. Br J Haematol 2008, 141:716-719.
10. Yurdakul S., Hekim N., Soysal T., Fresko I., Bavunoglu I., Ozbakir F., et al. Fibrinolytic activity and d-dimer levels in Behcet's syndrome. Clin Exp Rheumatol 2005, 23:S53-S58.
11. Espinosa G., Font J., Tassies D., Vidaller A., Deulofeu R., Lopez-Soto A., et al. Vascular involvement in Behcet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med 2002, 112:37-43.
12. Ates A., Duzgun N., Ulu A., Tiryaki A.O., Akar N. Factor V gene (1691A and 4070G) and prothrombin gene 20210A mutations in patients with Behcet's disease. Pathophysiol Haemost Thromb 2003, 33:157-163.
13. Dagan E., Baruch Y., Fiorilli M., Rozenbaum M., Rosner I., Gershoni-Baruch R. Vascular behcet and mutations in thrombogenic genes: methylene tetrahydrofolate reductase, factor v, and prothrombin. Genet Test Mol Biomarkers 2012, 16:30-35.
14. La Regina M., Orlandini F., Prisco D., Dentali F. Homocysteine in vascular Behcet disease: a meta-analysis. Arterioscler Thromb Vasc Biol 2010, 30:2067-2074.
15. Leiba M., Seligsohn U., Sidi Y., Harats D., Sela B.A., Griffin J.H., et al. Thrombophilic factors are not the leading cause of thrombosis in Behcet's disease. Ann Rheum Dis 2004, 63:1445-1449.
16. Ricart J.M., Vaya A., Todoli J., Calvo J., Villa P., Estelles A., et al. Thrombophilic risk factors and homocysteine levels in Behcet's disease in eastern Spain and their association with thrombotic events. Thromb Haemost 2006, 95:618-624.
17. International Study Group for Behcet's Disease Criteria for diagnosis of Behcet's disease. Lancet 1990, 335:1078-1080.
18. Cochran W.G. The combination of estimates from different experiments. Biometrics 1954, 10:101-129.
19. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
20. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
21. Bax L., Yu L.M., Ikeda N., Tsuruta H., Moons K.G. Development and validation of MIX: comprehensive free software for meta-analysis of causal research data. BMC Med Res Methodol 2006, 6:50.
22. Review Manager (RevMan) [computer program]. Version 5.0 2008, The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen.
23. Lesprit P., Wechsler B., Piette J.C., Du-Boutin L.T., Godeau P., Alhenc-Gelas M., et al. Activated protein C resistance caused by factor V Arg 506→Gln mutation has no role in thrombotic manifestations of Behcet's disease. Ann Rheum Dis 1995, 54:860.
24. Probst K., Fijnheer R., Rothova A. Endothelial cell activation and hypercoagulability in ocular Behcet's disease. Am J Ophthalmol 2004, 137:850-857.
25. Veli Z., Ozturk A., Egin Y., Yalcindag N., Akar N. The role of promoter polymorphisims of FVII gene in Behcet patients with thrombosis. Pathophysiol Haemost Thromb 2010, 37(SUPPL.. 1):247-288.
26. Yasar N.S., Salgur F., Cansu D.U., Kasifoglu T., Korkmaz C. Combined thrombophilic factors increase the risk of recurrent thrombotic events in Behcet's disease. Clin Rheumatol 2010, 29:1367-1372.
27. Cebeci F., Topcu E., Onsun N., Su O. Association between factor V Leiden gene mutation and systemic involvement in Behcet's disease. Turkderm Arch Turk D 2009, 43:21-24.
28. Gul A., Ozbek U., Ozturk C., Inanc M., Konice M., Ozcelik T. Coagulation factor V gene mutation increases the risk of venous thrombosis in Behcet's disease. Br J Rheumatol 1996, 35:1178-1180.
29. Mammo L., Al-Dalaan A., Bahabri S.S., Saour J.N. Association of factor V Leiden with Behcet's disease. J Rheumatol 1997, 24:2196-2198.
30. Gurgey A., Gurler A., Oner A.F., Mesci L., Kirazli S. Thrombomodulin levels in Behcet's disease with and without the factor V Leiden mutation. Clin Rheumatol 1998, 17:186-188.
31. Oner A.F., Gurgey A., Gurler A., Mesci L. Factor V Leiden mutation in patients with Behcet's disease. J Rheumatol 1998, 25:496-498.
32. Verity D.H., Vaughan R.W., Madanat W., Kondeatis E., Zureikat H., Fayyad F., et al. Factor V Leiden mutation is associated with ocular involvement in Behcet disease. Am J Ophthalmol 1999, 128:352-356.
33. Mader R., Ziv M., Adawi M., Lavi I. Thrombophilic factors and their relation to thromboembolic and other clinical manifestations in Behcet's disease. J Rheumatol 1999, 26:2404-2408.
34. Gul A., Aslantas A.B., Tekinay T., Konice M., Ozcelik T. Procoagulant mutations and venous thrombosis in Behcet's disease. Rheumatology (Oxford) 1999, 38:1298-1299.
35. Toydemir P.B., Elhan A.H., Tukun A., Toydemir R., Gurler A., Tuzuner A., et al. Effects of factor V gene G1691A, methylenetetrahydrofolate reductase gene C677T, and prothombin gene G20210A mutations on deep venous thrombogenesis in Behcet's disease. J Rheumatol 2000, 27:2849-2854.
36. Batioglu F., Atmaca L.S., Karabulut H.G., Beyza Sayin D. Factor V Leiden and prothrombin gene G20210A mutations in ocular Behcet disease. Acta Ophthalmol Scand 2003, 81:283-285.
37. Canataroglu A., Tanriverdi K., Inal T., Seydaoglu G., Arslan D., Ozbek S., et al. Methylenetetrahydrofolate reductase gene C677T mutation and plasma homocysteine level in Behcet's disease. Rheumatol Int 2003, 23:236-240.
38. Chen Y., Stanford M.R., Wallace G.R., Vaughan R.W., Kondeatis E., Fortune F. Factor V Leiden mutation does not correlate with retinal vascular occlusion in white patients with Behcet's disease. Br J Ophthalmol 2003, 87:1048-1049.
39. Gurgey A., Balta G., Boyvat A. Factor V Leiden mutation and PAI-1 gene 4G/5G genotype in thrombotic patients with Behcet's disease. Blood Coagul Fibrinolysis 2003, 14:121-124.
40. Ozkul Y., Evereklioglu C., Borlu M., Taheri S., Calis M., Dundar M., et al. 5,10-Methylenetetrahydrofolate reductase C677T gene polymorphism in Behcet's patients with or without ocular involvement. Br J Ophthalmol 2005, 89:1634-1637.
41. Silingardi M., Salvarani C., Boiardi L., Accardo P., Iorio A., Olivieri I., et al. Factor V Leiden and prothrombin gene G20210A mutations in Italian patients with Behcet's disease and deep vein thrombosis. Arthritis Rheum 2004, 51:177-183.
42. Tursen U., Kaya T.I., Eskandari G., Gunduz O., Yazar M., Ikizoglu G., et al. Association of factor V Leiden and prothrombin gene mutation with Behcet's disease. Arch Dermatol Res 2001, 293:537-539.
43. Soy M., Tanriverdi K., Kocak R., Ozbek S., Erken E. Factor V Leiden mutation in Behcet's disease. Ann Med Sci 2000, 9:22-23.
44. Mowla K., Zakerkish M., Samarbafzadeh A., Aleali A.M. Factor V leiden mutation in Behcet's disease and the relationship with clinical manifestations. Tehran Univ Med J 2010, 68:103-109.
45. Caramaschi P., Poli G., Bonora A., Volpe A., Tinazzi I., Pieropan S., et al. A study on thrombophilic factors in Italian Behcet's patients. Joint Bone Spine 2010, 77:330-334.
46. Shahram F., Shafiee N.M., Behmanesh M., Banihashemi A.T., Faridar A., Davatchi F. Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphism in patients with Behcet's disease. Clin Exp Rheumatol 2010, 28(SUPPL.. 60):105-168.
47. Karakus N., Yigit S., Kalkan G., Rustemoglu A., Inanir A., Gul U., et al. Association between the methylene tetrahydrofolate reductase gene C677T mutation and colchicine unresponsiveness in Behcet's disease. Mol Vis 2012, 18:1696-1700.
48. Kural-Seyahi E., Fresko I., Seyahi N., Ozyazgan Y., Mat C., Hamuryudan V., et al. The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003, 82:60-76.
49. Jadaon M.M. Epidemiology of activated protein C resistance and factor V Leiden mutation in the Mediterranean region. Mediterr J Hematol Infect Dis 2011, 3:e2011037.
50. Pineton de Chambrun M., Wechsler B., Geri G., Cacoub P., Saadoun D. New insights into the pathogenesis of Behcet's disease. Autoimmun Rev 2012, 11:687-698.